 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Phenazopyridine
Phenazopyridine Hydrochloride is light or dark red to dark violet. odorless, slightly bitter, crystalline powder. It has a specific local analgesic effect in the urinary tract, promptly relieving burning and pain. Phenazopyridine HCl tablets contain the following inactive ingredients:
lactose, magnesium stearate, microcrystalline cellulose, pharmaceutical
glaze, sodium starch glycolate, talc, and other ingredients.
Phenazopyridine HCl is excreted in the urine where it exerts a topical analgesic effect on the mucosa of the urinary tract. This action helps to relieve pain, burning, urgency and frequency. The precise mechanism of action is not known. The pharmacokinetic properties of Phenazopyridine HCl have not been determined.
Phenazopyridine HCl is rapidly excreted by the kidneys, with as much as
65% of an oral dose being excreted unchanged in the urine.
Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and Phenazopyridine HCl should be discontinued when symptoms are controlled. The analgesic action may reduce or eliminate the need for systemic analgesics
or narcotics. It is, however, compatible with antibacterial therapy and
can help to relieve pain and discomfort during the interval before antibacterial
therapy controls the infection. Treatment of a urinary tract infection
with Phenazopyridine HCl should not exceed 2 days because there is a lack
of evidence that the combined administration of Phenazopyridine HCl and
an antibacterial provides greater benefit than administration of the antibacterial
alone after 2 days. (See
Average adult dosage is 200 mg. 3 times a day after meals. When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days. HOW SUPPLIED Phenazopyridine Hydrochloride 100 mg tablets are supplied in bottles of 100 and 1000 tablets. 100 mg tablets are round, coated, deep maroon and printed 25. Phenazopyridine Hydrochloride 200 mg tablets are supplied in bottles of 100 and 1000 tablets. 200 mg tablets are caplet shaped, coated, deep maroon and printed CPC860. Store at controlled room temperature 15°- 30° C (59°- 86° F).
Headache, rash, pruritus and occasional gastrointestinal disturbances. An anaphylactoid-like reaction has been described. Methemoglobinemia, hemolytic anemia, renal and hepatic toxicity have been reported, usually at overdosage levels (see OVERDOSAGE section).
No information provided.
No information provided.
General A yellowish tinge of the skin or sclera may indicate accumulation due to impaired renal excretion and the need to discontinue therapy. The decline in renal function associated with advanced age should be kept in mind. NOTE: Patients should be informed that Phenazopyridine HCl produces a reddish-orange discoloration of the urine and may stain fabric. Staining of contact lenses has been reported. Laboratory Test Interaction Due to its properties as an azo dye, Phenazopyridine HCl may interfere with urinalysis based on spectrometry or color reactions. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term administration of Phenazopyridine HCl has induced neoplasia in rats (large intestine) and mice (liver). Although no association between Phenazopyridine HCl and human neoplasia has been reported, adequate epidemiological studies along these lines have not been conducted. Pregnancy Category B Reproduction studies have been performed in rats at doses up to 50 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to Phenazopyridine HCl. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers No information is available on the appearance of Phenazopyridine HCl,
or its metabolites in human milk.
|
| |||